United States
ARx, LLC is a pioneer in the development and manufacturing of drug-loaded dissolvable film and transdermal patch delivery systems. Founded in 2005 and headquartered in the United States, ARx is dedicated to enabling efficient and tailored delivery of drug compounds through transdermal patches and transmucosal thin films. The company's expertise lies in Quality by Design (QbD)-based controls, formulation, analytical testing, clinical and commercial batch production.
ARx's focus on transdermal and transmucosal routes of administration opens up new possibilities for drug products, enhancing bioavailability and improving patient compliance. Their diverse drug delivery systems include oral thin films, buccal, sublingual, and mucosal thin films, as well as transdermal and topical patches. This approach enriches patient well-being through robust drug delivery systems and offers an innovative way for the pharmaceutical industry to explore novel dosage forms for both new and existing products.
ARx, LLC's commitment to revolutionizing drug delivery and increasing patient well-being positions it at the forefront of the Health Care, Manufacturing, and Pharmaceutical industries. While their last investment and the associated investors are not publicly disclosed, the company's innovative solutions and impactful contributions to the healthcare sector make it a compelling potential venture capital opportunity.
